<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36689813</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN><JournalIssue CitedMedium="Internet"><Volume>645</Volume><PubDate><Year>2023</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation></Journal><ArticleTitle>MATR3 P154S knock-in mice do not exhibit motor, muscle or neuropathologic features of ALS.</ArticleTitle><Pagination><StartPage>164</StartPage><EndPage>172</EndPage><MedlinePgn>164-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2023.01.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0006-291X(23)00057-8</ELocationID><Abstract><AbstractText>Matrin 3 is a nuclear matrix protein that has many roles in RNA processing including splicing and transport of mRNA. Many missense mutations in the Matrin 3 gene (MATR3) have been linked to familial forms of amyotrophic lateral sclerosis (ALS) and distal myopathy. However, the exact role of MATR3 mutations in ALS and myopathy pathogenesis is not understood. To demonstrate a role of MATR3 mutations in&#xa0;vivo, we generated a novel CRISPR/Cas9 mediated knock-in mouse model harboring the MATR3 P154S mutation expressed under the control of the endogenous promoter. The P154S variant of the MATR3 gene has been linked to familial forms of ALS. Heterozygous and homozygous MATR3 P154S knock-in mice did not develop progressive motor deficits compared to wild-type mice. In addition, ALS-like pathology did not develop in nervous or muscle tissue in either heterozygous or homozygous mice. Our results suggest that the MATR3 P154S variant is not sufficient to produce ALS-like pathology in&#xa0;vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dominick</LastName><ForeName>Marissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houchins</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venugopal</LastName><ForeName>Vinisha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuberi</LastName><ForeName>Aamir R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Rare and Orphan Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutz</LastName><ForeName>Cathleen M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Rare and Orphan Disease Translational Center, The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meechooveet</LastName><ForeName>Bessie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Keuren-Jensen</LastName><ForeName>Kendall</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>David X</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, 85013, USA. Electronic address: david.medina2@barrowneuro.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS116385</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034521">Nuclear Matrix-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573692">matrin-3 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009135" MajorTopicYN="N">Muscular Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034521" MajorTopicYN="Y">Nuclear Matrix-Associated Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">MATR3 P154S mutation</Keyword><Keyword MajorTopicYN="N">Matrin 3</Keyword><Keyword MajorTopicYN="N">Mouse model</Keyword><Keyword MajorTopicYN="N">Neuropathology</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>23</Day><Hour>18</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36689813</ArticleId><ArticleId IdType="mid">NIHMS1869693</ArticleId><ArticleId IdType="pmc">PMC10046992</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2023.01.032</ArticleId><ArticleId IdType="pii">S0006-291X(23)00057-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen JJ, Overview of current and emerging therapies for amytrophic lateral sclerosis, Am. J. Manag. Care 26 (2020) S191&#x2013;S197. 10.37765/ajmc.2020.88483.</Citation><ArticleIdList><ArticleId IdType="doi">10.37765/ajmc.2020.88483</ArticleId><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME, Trial of Sodium Phenylbutyrate&#x2013;Taurursodiol for Amyotrophic Lateral Sclerosis, N. Engl. J. Med 383 (2020) 919&#x2013;930. 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA, ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?, Front. Neurosci 13 (2019) 1310. 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Feit H, Silbergleit A, Schneider LB, Gutierrez JA, Fitoussi RP, R&#xe9;y&#xe8;s C, Rouleau GA, Brais B, Jackson CE, Beckmann JS, Seboun E, Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31, Am. J. Hum. Genet 63 (1998) 1732&#x2013;1742. 10.1086/302166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302166</ArticleId><ArticleId IdType="pmc">PMC1377645</ArticleId><ArticleId IdType="pubmed">9837826</ArticleId></ArticleIdList></Reference><Reference><Citation>Senderek J, Garvey SM, Krieger M, Guergueltcheva V, Urtizberea A, Roos A, Elbracht M, Stendel C, Tournev I, Mihailova V, Feit H, Tramonte J, Hedera P, Crooks K, Bergmann C, Rudnik-Sch&#xf6;neborn S, Zerres K, Lochm&#xfc;ller H, Seboun E, Weis J, Beckmann JS, Hauser MA, Jackson CE, Autosomal-Dominant Distal Myopathy Associated with a Recurrent Missense Mutation in the Gene Encoding the Nuclear Matrix Protein, Matrin 3, Am. J. Hum. Genet 84 (2009) 511&#x2013;518. 10.1016/j.ajhg.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC2667977</ArticleId><ArticleId IdType="pubmed">19344878</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller TJ, Kraya T, Stoltenburg-Didinger G, Hanisch F, Kornhuber M, Stoevesandt D, Senderek J, Weis J, Baum P, Deschauer M, Zierz S, Phenotype of matrin-3-related distal myopathy in 16 German patients, Ann. Neurol 76 (2014) 669&#x2013;680. 10.1002/ana.24255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24255</ArticleId><ArticleId IdType="pubmed">25154462</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo JD Rothstein, ITALSGEN, C. Drepper, M. Sendtner, A.B. Singleton, J.P. Taylor, M.R. Cookson, G. Restagno, M. Sabatelli, R. Bowser, A. Chi&#xf2;, B.J. Traynor, Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis, Nat. Neurosci 17 (2014) 664&#x2013;666. 10.1038/nn.3688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangi G, Lattante S, Doronzio PN, Conte A, Tasca G, Monforte M, Patanella AK, Bisogni G, Meleo E, La Spada S, Zollino M, Sabatelli M, Matrin 3 variants are frequent in Italian ALS patients, Neurobiol. Aging 49 (2017) 218.e1&#x2013;218.e7. 10.1016/j.neurobiolaging.2016.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.09.023</ArticleId><ArticleId IdType="pubmed">28029397</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Li J, Tang L, Zhang N, Fan D, MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis, Neurobiol. Aging 38 (2016) 218.e3&#x2013;218.e4. 10.1016/j.neurobiolaging.2015.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.11.023</ArticleId><ArticleId IdType="pubmed">26708275</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K-P, Tsai P-C, Liao Y-C, Chen W-T, Tsai C-P, Soong B-W, Lee Y-C, Mutational analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis, Neurobiol. Aging 36 (2015) 2005.e1&#x2013;4. 10.1016/j.neurobiolaging.2015.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.02.008</ArticleId><ArticleId IdType="pubmed">25771394</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblond CS, Gan-Or Z, Spiegelman D, Laurent SB, Szuto A, Hodgkinson A, Dionne-Laporte A, Provencher P, de Carvalho M, Orr&#xf9; S, Brunet D, Bouchard J-P, Awadalla P, Dupr&#xe9; N, Dion PA, Rouleau GA, Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis, Neurobiol. Aging 37 (2016) 209.e17&#x2013;209.e21. 10.1016/j.neurobiolaging.2015.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.09.013</ArticleId><ArticleId IdType="pubmed">26493020</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Carmichael GG, The fate of dsRNA in the nucleus: a p54(nrb)-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs, Cell 106 (2001) 465&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525732</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton M, Lerenthal Y, Wang S-Y, Chen DJ, Shiloh Y, Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response, Cell Cycle Georget. Tex 9 (2010) 1568&#x2013;1576. 10.4161/cc.9.8.11298.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.9.8.11298</ArticleId><ArticleId IdType="pubmed">20421735</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton M, Elkon R, Borodina T, Davydov A, Yaspo M-L, Halperin E, Shiloh Y, Matrin 3 binds and stabilizes mRNA, PloS One 6 (2011) e23882. 10.1371/journal.pone.0023882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023882</ArticleId><ArticleId IdType="pmc">PMC3157474</ArticleId><ArticleId IdType="pubmed">21858232</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallego-Iradi MC, Clare AM, Brown HH, Janus C, Lewis J, Borchelt DR, Subcellular Localization of Matrin 3 Containing Mutations Associated with ALS and Distal Myopathy, PloS One 10 (2015) e0142144. 10.1371/journal.pone.0142144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142144</ArticleId><ArticleId IdType="pmc">PMC4631352</ArticleId><ArticleId IdType="pubmed">26528920</ArticleId></ArticleIdList></Reference><Reference><Citation>Iradi MCG, Triplett JC, Thomas JD, Davila R, Crown AM, Brown H, Lewis J, Swanson MS, Xu G, Rodriguez-Lebron E, Borchelt DR, Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy, Sci. Rep 8 (2018) 4049. 10.1038/s41598018-21371-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598018-21371-4</ArticleId><ArticleId IdType="pmc">PMC5840295</ArticleId><ArticleId IdType="pubmed">29511296</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer A, Garcia-Mansfield K, Singh G, Bakkar N, Pirrotte P, Bowser R, ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export, Sci. Rep 7 (2017) 14529. 10.1038/s41598-017-14924-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14924-6</ArticleId><ArticleId IdType="pmc">PMC5674072</ArticleId><ArticleId IdType="pubmed">29109432</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo JD Rothstein, ITALSGEN, C. Drepper, M. Sendtner, A.B. Singleton, J.P. Taylor, M.R. Cookson, G. Restagno, M. Sabatelli, R. Bowser, A. Chi&#xf2;, B.J. Traynor, Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis, Nat. Neurosci 17 (2014) 664&#x2013;666. 10.1038/nn.3688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M, Chen J, Kuang L, Arenas A, Zhai J, Zhu H, Gal J, Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS, Biochim. Biophys. Acta 1862 (2016) 2004&#x2013;2014. 10.1016/j.bbadis.2016.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.07.015</ArticleId><ArticleId IdType="pmc">PMC5055831</ArticleId><ArticleId IdType="pubmed">27460707</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi A, Takanashi K, FUS interacts with nuclear matrix-associated protein SAFB1 as well as Matrin3 to regulate splicing and ligand-mediated transcription, Sci. Rep 6 (2016). 10.1038/srep35195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep35195</ArticleId><ArticleId IdType="pmc">PMC5059712</ArticleId><ArticleId IdType="pubmed">27731383</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreser A, Vollrath JT, Sechi A, Johann S, Roos A, Yamoah A, Katona I, Bohlega S, Wiemuth D, Tian Y, Schmidt A, Vervoorts J, Dohmen M, Beyer C, Anink J, Aronica E, Troost D, Weis J, Goswami A, The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins, Cell Death Differ 24 (2017) 1655&#x2013;1671. 10.1038/cdd.2017.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.88</ArticleId><ArticleId IdType="pmc">PMC5596426</ArticleId><ArticleId IdType="pubmed">28622300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada M, Doi H, Koyano S, Kubota S, Fukai R, Hashiguchi S, Hayashi N, Kawamoto Y, Kunii M, Tanaka K, Takahashi K, Ogawa Y, Iwata R, Yamanaka S, Takeuchi H, Tanaka F, Matrin 3 Is a Component of Neuronal Cytoplasmic Inclusions of Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis, Am. J. Pathol 188 (2018) 507&#x2013;514. 10.1016/j.ajpath.2017.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2017.10.007</ArticleId><ArticleId IdType="pubmed">29128563</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer A, Garcia-Mansfield K, Singh G, Bakkar N, Pirrotte P, Bowser R, ALS Associated Mutations in Matrin 3 Alter Protein-Protein Interactions and Impede mRNA Nuclear Export, Sci. Rep 7 (2017) 14529. 10.1038/s41598-017-14924-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14924-6</ArticleId><ArticleId IdType="pmc">PMC5674072</ArticleId><ArticleId IdType="pubmed">29109432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprunger ML, Lee K, Sohn BS, Jackrel ME, Molecular determinants and modifiers of Matrin-3 toxicity, condensate dynamics, and droplet morphology, IScience 25 (2022) 103900. 10.1016/j.isci.2022.103900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103900</ArticleId><ArticleId IdType="pmc">PMC8889142</ArticleId><ArticleId IdType="pubmed">35252808</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik AM, Miguez RA, Li X, Ho Y-S, Feldman EL, Barmada SJ, Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization, ELife 7 (2018) e35977. 10.7554/eLife.35977.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.35977</ArticleId><ArticleId IdType="pmc">PMC6050042</ArticleId><ArticleId IdType="pubmed">30015619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao CS, van Bruggen R, Kim JR, Chen XXL, Chan C, Lee J, Cho WI, Zhao M, Arndt C, Maksimovic K, Khan M, Tan Q, Wilson MD, Park J, Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS, Nat. Commun 11 (2020) 5304. 10.1038/s41467-020-18949-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18949-w</ArticleId><ArticleId IdType="pmc">PMC7576598</ArticleId><ArticleId IdType="pubmed">33082323</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bruggen R, Maksimovic K, You J, Tran DD, Lee HJ, Khan M, Kao CS, Kim JR, Cho W, Chen XXL, Park J, MATR3 F115C knock-in mice do not exhibit motor defects or neuropathological features of ALS, Biochem. Biophys. Res. Commun 568 (2021) 48&#x2013;54. 10.1016/j.bbrc.2021.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.06.052</ArticleId><ArticleId IdType="pubmed">34182213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Yamashita S, Hara K, Doki T, Tawara N, Ikeda T, Misumi Y, Zhang Z, Matsuo Y, Nagai M, Kurashige T, Maruyama H, Ando Y, A mutant MATR3 mouse model to explain multisystem proteinopathy, J. Pathol 249 (2019) 182&#x2013;192. 10.1002/path.5289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5289</ArticleId><ArticleId IdType="pubmed">31056746</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney C, Rayaprolu S, Howard J, Fromholt S, Brown H, Collins M, Cabrera M, Duffy C, Siemienski Z, Miller D, Borchelt DR, Lewis J, Analysis of spinal and muscle pathology in transgenic mice overexpressing wild-type and ALS-linked mutant MATR3, Acta Neuropathol. Commun 6 (2018) 137. 10.1186/s40478-018-0631-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0631-0</ArticleId><ArticleId IdType="pmc">PMC6299607</ArticleId><ArticleId IdType="pubmed">30563574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N, Kour S, Anderson EN, Rajasundaram D, Pandey UB, RNA-recognition motif in Matrin-3 mediates neurodegeneration through interaction with hnRNPM, Acta Neuropathol. Commun 8 (2020) 138. 10.1186/s40478-020-01021-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-01021-5</ArticleId><ArticleId IdType="pmc">PMC7437177</ArticleId><ArticleId IdType="pubmed">32811564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallego-Iradi MC, Strunk H, Crown AM, Davila R, Brown H, Rodriguez-Lebron E, Borchelt DR, N-terminal sequences in matrin 3 mediate phase separation into droplet-like structures that recruit TDP43 variants lacking RNA binding elements, Lab. Invest 99 (2019) 1030&#x2013;1040. 10.1038/s41374-019-0260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-019-0260-7</ArticleId><ArticleId IdType="pmc">PMC6857798</ArticleId><ArticleId IdType="pubmed">31019288</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Atienzar S, Dalgard CL, Ding J, Chi&#xf2; A, Alba C, Hupalo DN, Wilkerson MD, Bowser R, Pioro EP, Bedlack R, Traynor BJ, Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred, Neurology 95 (2020) 1015&#x2013;1018. 10.1212/WNL.0000000000011064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011064</ArticleId><ArticleId IdType="pmc">PMC7734922</ArticleId><ArticleId IdType="pubmed">33077544</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Oiwa K, Murata Y, Komine O, Sobue A, Endo F, Takahashi E, Yamanaka K, ALS-linked TDP-43M337V knock-in mice exhibit splicing deregulation without neurodegeneration, Mol. Brain 13 (2020) 8. 10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S-L, Wu L-S, Lee M, Chang C-W, Cheng W-C, Fang Y-S, Chen Y-R, Cheng P-L, Shen C-KJ, A robust TDP-43 knock-in mouse model of ALS, Acta Neuropathol. Commun 8 (2020) 3. 10.1186/s40478-020-0881-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0881-5</ArticleId><ArticleId IdType="pmc">PMC6975031</ArticleId><ArticleId IdType="pubmed">31964415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>